JM

Joe Markson

Healthcare venture capital at Novo Ventures

San Francisco, California

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • Principal

    2024

  • Senior Associate, Venture Investments

    2022 - 2024

  • Associate, Ventures Investments

    2020 - 2021

  • Board Observer

    2023

  • Director Board of Directors

    2023

  • Board Observer

    2021

2020 - 2021

  • Board Observer

    2020 - 2021

    Board Observer from Novo Ventures' Series B investment through Reneo's IPO (NASDAQ: RPHM).

2020 - 2020

  • Strategy Lead

    2020 - 2020

    Technology development strategy

  • Portfolio Manager (consultant)

    2020 - 2020

    Strategic R&D portfolio planning

  • Consultant

    2018 - 2020

    Management consultant working exclusively in BCG's Healthcare and PIPE (Principle Investor / Private Equity) practices. Extensive experience across the healthcare spectrum - from R&D strategy and portfolio evaluation for biopharma clients, to medtech and biopharma manufacturing, to insurance claims data analysis. Also extensive experience with buy-side due diligence work for both private equity and strategic buyer clients across a variety of industries (healthcare software, financial services, Internet of Things). Projects have included: -R&D strategy refresh for the head of R&D at a biopharma client -R&D portfolio evaluation and rationalization for a biopharma client -Planning for manufacturing insourcing at a Medtech client -Design and business case for a digital transformation of manufacturing at a Biopharma client -Patient segmentation and opportunity identification based on analysis of hundreds of millions of health insurance claims data for an insurer -Due diligence projects: 4 buy-side due diligences across healthcare software, financial services, and Internet of Things

2013 - 2018

  • Postdoctoral Scholar

    2013 - 2018

    Postdoc with Michael Elowitz, pioneer in systems and synthetic biology. I used synthetic and systems biology approaches to studying development. I employed both experimental and computational techniques, including timelapse fluorescence microscopy, mammalian cell culture and genetic engineering, flow cytometry, dynamical systems modeling, parameter estimation, analysis of timelapse microscopy data.

2010 - 2013

  • Postdoctoral associate

    2010 - 2013

    Continuation of my PhD research in the O'Shea lab